Traditional culture and susceptibility testing can take two to three days to name an organism and its resistance pattern. Rapid molecular diagnostics are compressing that timeline dramatically.
Multiplex PCR panels and rapid identification directly from positive blood cultures can detect pathogens and key resistance genes within hours. That speed lets clinicians move from broad empiric therapy to targeted treatment sooner — and, just as importantly, de-escalate when broad coverage is unnecessary.
The technology delivers its full benefit only when paired with stewardship. A fast result that no one acts on changes nothing; a fast result reviewed with a stewardship team changes therapy in real time.
These tools do not replace the antibiogram, the local snapshot of resistance that guides empiric choices. They complement it, adding patient-level precision on top of population-level guidance.